Data from clinical trial supported by the Parker Institute for Cancer Immunotherapy, Cancer Research Institute presented at AACR 2019
ATLANTA – March 31, 2019 – Combining immunotherapy with chemotherapy shows promise for treating advanced pancreatic cancer, shrinking tumors in a majority of evaluable patients – 20 out of 24 – as of an interim analysis of phase 1b data from an ongoing trial. The findings are being unveiled today at the American Association for Cancer Research (AACR) 2019 Annual Meeting in Atlanta. Parker Institute for Cancer Immunotherapy (PICI) researchers at the University of Pennsylvania will present the results on behalf of PICI investigators from seven institutions where the study is being conducted.
The strategy involves tackling the tough-to-treat tumor with a three-pronged attack using standard-of-care chemotherapy plus two types of immunotherapy: an experimental CD40 antibody designed to rev up the immune system and PD-1 checkpoint inhibitor that takes the brakes off the immune system.>>>>>>>reed the whole article